The distinction is more than taxonomic housekeeping. Liquid-phase vesicles, which have fuelled a decade of biomarker discovery and therapeutic development, are subject to dilution, clearance and non-specific biodistribution the moment they enter circulation. Matrix-bound vesicles, by contrast, never leave home. They stay tethered to the fibrous network of collagen, glycoproteins and other macromolecules that gives tissue its structure, delivering their cargo of proteins, lipids and microRNAs to neighbouring cells in a strictly local, context-dependent manner. In doing so, they function not merely as passengers within the matrix but as functional components of it, shaping tissue development, regeneration and day-to-day homeostasis.

The technical case for treating matrix-bound vesicles as a separate population rests on molecular evidence. Lipidomic and RNA sequencing studies of vesicles extracted from decellularized extracellular matrix bioscaffolds have revealed cargo profiles that differ measurably from those of vesicles harvested from the surrounding fluid. Proteomic comparisons of liquid-phase and matrix-bound vesicles grown in both two-dimensional and three-dimensional cell cultures reinforce the picture of two biochemically distinct populations. Matrix-bound vesicles carry tissue-specific protein and microRNA signatures, suggesting that they act as regulatory components of the matrix rather than as incidental debris trapped in its fibres.

That tissue specificity is one of the most striking features of the new framework. Vesicles isolated from decellularized cardiac, skeletal muscle, bone and other tissues recapitulate the angiogenic and immunomodulatory properties of their parent matrices, and their microRNA profiles differ from tissue to tissue. In bone, matrix vesicle cargo such as the microRNA miR-125b accumulates within the mineralized matrix and inhibits bone resorption in mouse models. In skeletal muscle, vesicle-associated interleukin-33 has been shown to initiate a pro-regenerative shift in macrophage phenotype after injury, supporting functional recovery. The vesicles, in effect, carry a molecular record of the tissue they came from—and a set of instructions appropriate to that tissue.

The review also documents how this record changes with age and disease, and the implications are unsettling. Studies of aged breast tissue show that matrix-bound vesicles from older matrices carry cargo that promotes invasiveness in breast epithelial and cancer cells, suggesting that the aged microenvironment itself can actively contribute to tumour progression. Cardiac tissue-resident vesicles regulate fibroblast activation in an age- and sex-dependent manner, and multi-omics profiling of young and aged plasma and matrix-bound vesicles has identified anti-fibrotic microRNAs enriched in the young versions, with therapeutic activity validated in a heart-on-a-chip model. In colorectal cancer, vesicles trapped in decellularized tumour matrix preserve disease-associated signatures of the tumour microenvironment, while cancer-associated fibroblasts have been shown to produce matrix-bound vesicles that influence endothelial cell function. The matrix, in other words, is not a passive scaffold but an active archive of pathological state.

Therapeutically, the localized nature of matrix-bound vesicles is both their greatest asset and their central challenge. Because they act where they are placed, they are natural candidates for integration into engineered tissues and biomaterial delivery platforms. Matrix-bound vesicles embedded in cartilaginous extracellular matrix have enabled functional reconstruction of tracheal defects, vesicles from decellularized tumours have been used as platforms for targeting parent tumour cells and tumour-associated stromal cells, and injectable microsphere systems are being developed for sustained delivery in adipose tissue engineering. Immunomodulatory matrix-bound vesicles derived from urinary bladder matrix have mitigated influenza-mediated lung inflammation while preserving antiviral responses, eased rheumatoid arthritis in preclinical models, and alleviated particulate-induced periprosthetic osteolysis. Recent work even suggests these vesicles can accumulate in bone marrow and induce durable epigenetic changes in myeloid progenitors and macrophages, hinting at effects that outlast the vesicles themselves.

Compared with their liquid-phase cousins, matrix-bound vesicles may also sidestep some of the biodistribution problems that have plagued systemic vesicle therapies. Circulating vesicles must survive the bloodstream, cross vascular barriers and find the right tissue before releasing their cargo, and much of the dose is lost along the way. A vesicle pre-positioned within an implanted scaffold or hydrogel faces no such gauntlet. The trade-off is that delivery becomes inseparable from the biomaterial itself: the scaffold must retain the vesicles, present them to infiltrating host cells and release them, if release is desired, on a controlled schedule. This couples vesicle therapy directly to the maturing field of engineered extracellular matrices, decellularized scaffolds and bioprinted tissues.

Getting there, the authors caution, requires solving problems that the liquid-phase vesicle field has only partially addressed. Isolation of matrix-bound vesicles depends on decellularization protocols whose harshness can alter yield, purity and function, and different isolation methods produce vesicles with different biological behaviour. Characterization remains hampered by the heterogeneity of vesicle populations and by the lack of standardized reporting, although community frameworks such as the MISEV guidelines are pushing the field toward rigor. Downstream, translating cargo profiles into diagnostics or therapeutics will demand bioinformatics integration across proteomics, lipidomics and transcriptomics, and manufacturing clinical-grade material will require scalable, validated processes. The review singles out innovations in isolation, characterization, bioinformatics and bioengineered delivery as the four pillars on which translational success will rest.

What emerges from the analysis is a reframing of how biologists should think about the space between cells. The extracellular matrix has long been appreciated as a mechanical and structural environment that influences stem cell fate, angiogenesis and fibrosis. The new work positions matrix-bound vesicles as the signalling layer of that environment—a distributed, tissue-encoded communication network that operates alongside, and distinct from, the systemic vesicle traffic carried in blood, urine, saliva and other biofluids. If the framework holds, diagnostics could one day read the vesicular archive embedded in a biopsy or decellularized scaffold to reconstruct a tissue’s recent history, and regenerative therapies could seed engineered implants with vesicles pre-loaded with the molecular instructions a healing tissue needs. The quiet postal service in the matrix, long overlooked, may prove to be one of the most consequential mail routes in the body.

Subject of Research: Matrix-bound extracellular vesicles as tissue-specific, matrix-anchored mediators of local intercellular signalling in health, ageing and disease

Article Title: Matrix-bound extracellular vesicles

Article References: Matrix-bound extracellular vesicles. (n.d.). https://doi.org/10.1038/s44222-026-00477-9

Image Credits: AI Generated

DOI: 10.1038/s44222-026-00477-9

Keywords: extracellular vesicles, matrix-bound vesicles, extracellular matrix, tissue engineering, regenerative medicine, biomarkers, microRNA, decellularization, immunomodulation, tumour microenvironment, drug delivery, Nature Reviews Bioengineering